Real-world performance of the MiniMed™ 670G system in Europe.

Julien Da SilvaEmanuele BosiJohan JendleArcelia ArrietaJavier CastanedaBenyamin GrossmanToni L CorderoJohn ShinOhad Cohen

Published in: Diabetes, obesity & metabolism (2021)

Most MiniMed 670G system users in Europe achieved TIR more than 70% and GMI less than 7% while minimizing hypoglycaemia, in a real-world environment. These international consensus-met outcomes were enabled by automated insulin delivery meeting real-time insulin requirements adapted to each individual user.

Keyphrases

type diabetes
glycemic control
machine learning
high throughput
tyrosine kinase
insulin resistance
clinical practice